⚠️

Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.

Read our methodology →

Adenike TinubuM.D.

Family Practice · Opelousas, LA 70570

NPI: 1306055652

Share:

26

🟡 Moderate

ML Fraud Detection Score: 96%

Machine learning model identifies prescribing patterns consistent with confirmed fraud cases. This is a statistical indicator, not an accusation.

Learn more →

Risk Flags

High antipsychotic prescribing (65+)Opioid + benzodiazepine co-prescriberExtreme fills per patient

Risk indicators are statistical patterns, not allegations. Learn more

30,800

Total Claims

$1.9M

Drug Cost

448

Beneficiaries

$4,284

Cost/Patient

Risk Score Breakdown 26/100

Low (0)Moderate (15)Elevated (30)High (50+)
Elderly antipsychotic prescribing+10
Opioid + benzodiazepine combo+8
High fills per patient+5

Score components are additive. Read full methodology

Peer Comparison vs. 106,889 Family Practice providers

+207%

Opioid rate vs peers

7.9% vs 2.6% avg

+301%

Cost per patient vs peers

$4,284 vs $1,068 avg

+13%

Brand preference vs peers

10.1% vs 9.0% avg

⚠️ Opioid + Benzodiazepine Co-Prescriber

This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.

🔎 Data Overview

🤖

Our machine learning model — trained on 281 confirmed fraud cases — gives this provider a "Very High" fraud-pattern score. All 20 decision trees in our ensemble model agree that this provider's prescribing patterns resemble those of confirmed fraud cases. This is a statistical finding, not an accusation.

💊

Opioid rate is 207% above Family Practice peers. This is a significant deviation that may reflect a specialized patient population or concerning prescribing patterns.

⚠️

This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.

Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.

Opioid Prescribing

7.9%

Opioid Rate

2,439

Opioid Claims

$55K

Opioid Cost

Long-Acting Rate

Brand vs Generic

90% generic

Brand: 3,110 claims · $1.5M

Generic: 27,584 claims · $444K

Top Prescribed Drugs

Drug (Generic)ClaimsCost
Empagliflozin338$222K
Fluticasone/Umeclidin/Vilanter286$197K
Linagliptin232$146K
Sitagliptin Phosphate191$144K
Semaglutide102$102K
Budesonide/Glycopyr/Formoterol105$71K
Dapagliflozin Propanediol114$71K
Hydrocodone/Acetaminophen2,136$49K
Insulin Glargine,hum.Rec.Anlog94$44K
Fluticasone/Vilanterol102$43K
Sacubitril/Valsartan60$43K
Apixaban74$35K
Linaclotide62$35K
Rivaroxaban47$32K
Insulin Glargine,hum.Rec.Anlog24$23K

Prescribing Profile

180

Unique Drugs

$547K

IRA Negotiated Drugs

$120K

GLP-1 Drugs

26.0

Anomaly Score

Patient Profile

66

Avg Age

51%

Female

1.78

Avg Risk Score

Explore More

Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data